Business
Grant of Options and PDMR Dealings
Grant of Options and PDMR Dealings.
About this update from Theracryf Plc
[{"type":"text","content":"\n\n\n \nTheraCryf plc\n(\"TheraCryf\", the \"Company\" or the \"Group\")\nGrant of Options, Surrender of Existing Options and PDMR Dealings\nAlderley Park, UK - 29 August 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that certain employees and Persons Discharging Managerial Responsibility (\"PDMR\"), including former Chronos Therapeutics Ltd (\"Chronos\") employees and consultants deemed essential to the development of the acquired assets, have been granted options (the \"Options\") over a total of 28,731,578 ordinary shares of 0.25 pence each in the Company (\"Ordinary Shares\"), exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the TheraCryf plc Long Term Incentive Plan (\"LTIP\"), as amended.\n\n\n\n\n\n\n\nNumber of Existing Ordinary Shares held\n\n\nCurrent Options Held\n\n\nOptions Surrendered\n\n\nNew Options Granted\n\n\nAggregate number of Options post grant\n\n\n% of issued share capital under Option including this award\n\n\n\n\nDr Huw Jones (CEO, Executive Director)\n\n\n 3,184,793\n\n\n 6,081,613\n\n\n 6,081,613\n\n\n 10,894,238\n\n\n 10,894,238\n\n\n2.55%\n\n\n\n\nToni Hänninen (CFO, Executive Director)*\n\n\n 1,000,000\n\n\n \n\n\n \n\n\n 3,029,925\n\n\n 3,029,925\n\n\n0.71%\n\n\n\n\nDr Helen Kuhlman (PDMR)\n\n\n 1,055,744\n\n\n 2,446,099\n\n\n &...